Wedbush raised the firm’s price target on Kiniksa (KNSA) to $44 from $38 and keeps an Outperform rating on the shares. The firm says the company heads into Q3 earnings on the heels of another strong quarter that further reinforced Arcalyst’s durable growth trajectory in recurrent pericarditis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA: